SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as investors pivot toward the space sector following the company's new NASA contract and rising anticipation for the upcoming Artemis II mission. The community is actively debating the stock's momentum, with intense discussions focused on potential short squeezes, institutional accumulation, and the broader implications of a possible SpaceX IPO.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is facing intense scrutiny and negative sentiment from retail investors, driven by a perceived lack of communication from leadership regarding the Helios data center project and disappointment over the company's performance compared to sector peers. The community is actively debating the stock's future, with many expressing frustration over the recent delisting from the TSX, stagnant price action, and a lack of clear catalysts to break the current trading range.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on March 20, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings is trending as investors bet on a potential short squeeze, citing its low float and high institutional ownership reminiscent of previous high-volatility runners. The community is actively discussing recent patent news and corporate updates while speculating on the impact of potential future government defense contracts.

Tema ETF Trust - Tema Space Innovators ETF

The newly launched Tema Space Innovators ETF is gaining significant traction among retail traders due to its direct exposure to SpaceX ahead of an anticipated public listing. The community is actively debating the ETF's low liquidity and AUM structure, with some participants viewing it as a high-potential momentum play while others express skepticism regarding its underlying holdings.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is seeing intense market interest following the announcement of a major multi-year AI infrastructure contract, with the community actively speculating on its potential for a significant short squeeze due to the stock's low float. Traders are closely monitoring the price action and volume levels, debating whether this partnership validates the company's long-term growth or if the current market dynamics suggest further volatility ahead.

Mezo is the onchain Bitcoin banking platform owned by its users. Users can access self-service Bitcoin finance without interacting with loan officers, undergoing credit checks, or observing operational hours. It’s just you, your Bitcoin, and permissionless access to financial services 24/7.  Traditional banks profit from your deposits while charging you for access to your own money. Two-sided lending markets trap you with 8-9% variable rates that can spike unpredictably, especially in decentralized financial systems. Both systems put middlemen between you and your wealth.  Mezo eliminates them all, giving you the power to manage your finances intelligently on your own terms.  Deposit Bitcoin as collateral, mint MUSD (a dollar-pegged stablecoin), and use it however you need. Your Bitcoin stays yours while MUSD provides you with instant liquidity. Fixed rates start as low as 1% and stay fixed for the entire life of the loan.  This is self-service banking with complete autonomy. Unlike any traditional banking experience, there are no minimum payments, set repayment schedules, or penalties for early repayment. Close your position tomorrow or keep it open for years.  It’s your Bitcoin and your decision on what to do with it.

MEZO

Mezo is drawing significant investor interest following its listing on Coinbase as a Bitcoin-native economic layer designed to expand utility through staking and governance. Community members are actively debating the token's long-term potential compared to past Bitcoin-based projects while navigating current trading availability across exchange platforms.

Mega Fortune Co., Ltd. operates as a holding company which provides information technology services. It specializes in delivering comprehensive IoT solutions and services across various industries. The firm offers low carbon property management, energy, stock and GreenTech management services. The company was founded in 2011 and is headquartered in Hong Kong.

Mega Fortune Co Ltd.

Mega Fortune Company Limited

Mega Fortune Company Limited is trending as traders speculate on potential volatility and price swings common with low-float, recent Hong Kong-based IPOs. Community sentiment is deeply divided, with many actively debating whether the stock will mirror historical 'pump and dump' cycles or serve as an asymmetric opportunity for massive gains.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is currently seeing heightened investor interest driven by strong earnings results, improved full-year guidance, and a strategic AI infrastructure partnership with SK Telecom. The community is actively debating the stock's long-term potential as an AI-play, with many focusing on its role in high-performance computing pipelines and debating its valuation relative to broader industry growth.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is seeing significant market activity and intense community discussion following the FDA's granting of Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia. Investors are closely monitoring upcoming clinical trial readouts while debating the company's long-term potential, with many highlighting its strong cash runway and precision psychiatry pipeline as key drivers for long-term growth.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently trending due to community excitement surrounding its post-quantum cryptography features, which are being highlighted in the context of broader industry discussions on quantum security. Investors are actively debating the token's long-term potential and institutional readiness as they monitor technical price action and recent governance developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Codexis, Inc. (NASDAQ:CDXS) Grows By 26.2%

Codexis, Inc. (NASDAQ:CDXS - Get Free Report) saw a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 9,161,843 shares, an...

Codexis (NASDAQ:CDXS) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen upgraded shares of Codexis from a "strong sell" rating to a "hold" rating in a report on Saturday...

Why Did Codexis (CDXS) Stock Soar Nearly 38% After Hours?

Codexis shares jumped 37.8% in after-hours trading after the company reported a profitable fourth quarter and full-year 2025 revenue growth.read more...

Codexis (CDXS) Q4 2025 Earnings Call Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Codexis Q4 Earnings Call Highlights

Codexis (NASDAQ:CDXS) used its fourth-quarter and full-year 2025 earnings call to highlight progress behind its strategic focus on RNA medicines, with management emphasizing technical milestones for...

Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of +2,100.00% and +1.61%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Codexis (NASDAQ:CDXS) Releases Earnings Results, Beats Expectations By $0.10 EPS

Codexis (NASDAQ:CDXS - Get Free Report) announced its quarterly earnings results on Wednesday. The biotechnology company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.01 by...

Codexis Targets 2026 Inflection as CEO Touts ECO Synthesis Push in RNA Manufacturing at TD Cowen Conf

Codexis (NASDAQ:CDXS) President and CEO Alison Moore outlined the company's strategic focus on RNA medicines manufacturing at TD Cowen's 46th Annual Health Care Conference, emphasizing expected...

Liquidia Corporation (LQDA) Surpasses Q4 Earnings and Revenue Estimates

Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +100.00% and +19.34%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>The siRNA material will support the preclinical development of a therapeutic candidate for the treatment of a cardiovascular condition, the company said.</li><li>In January, Codexis tied up with Axolabs to evaluate its ECO Synthesis platform.</li><li>The firm is expected to post its Q4 results next week, with Wall Street expecting revenue to surge around 67% to $35.8 million.</li></ul>Shares of Codexis, Inc. (CDXS) gained 7% on Wednesday after the company announced an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform.Codexis, however, did not disclose the name of the firm.The siRNA material will support the preclinical development of a therapeutic candidate for the treatment of a cardiovascular condition. Codexis’ ECO Synthesis platform is built to enable scalable, high-fidelity production of complex siRNA therapies.As RNA-based medicines move beyond rare diseases into larger patient populations, manufacturing requirements are rising significantly. The company believes its enzymatic technology is well-positioned to meet this growing demand.&nbsp;“We are excited about this relationship as it represents an important entry point into what could become a high-volume opportunity,” said Alison Moore, President and Chief Executive Officer of Codexis.<h2 class="st-heading-2">Axolabs Partnership For ECO Synthesis Platform</h2>The news follows Codexis’ agreement earlier this year with Axolabs to evaluate its ECO Synthesis platform, a step that could lead to future licensing opportunities and wider adoption of the technology in RNA manufacturing.Kathleen Campau, Senior Director of Operations at Axolabs, had said that the technology could play a pivotal role in the future large-scale manufacturing of therapeutic oligonucleotides by enabling more sustainable and cost-effective production.The biotech firm is expected to post its fourth-quarter results next week, with Wall Street expecting revenue to surge around 67% to $35.8 million, according to Fiscal.ai data, while loss is expected to narrow to $0.04 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CDXS">CDXS</a> on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.One user believes the latest development adds “momentum and validation.”<stembedurl>https://stocktwits.com/Camille65/message/646560686</stembedurl>Another user noted they were neutral earlier but turned bullish on the stock after reading the announcement.<stembedurl>https://stocktwits.com/10xMoonstocks/message/646571515</stembedurl>The stock has been under heavy selling pressure this year, declining more than 36%Read also: &nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crwv-stock-coreweave-perplexity-cloud-partnership/cZd9F11RI5u">CoreWeave Inks Deal With Perplexity – CRWV Stock Gains 6% Pre-Market, On Track To Arrest Post Earnings Slump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

Why Did CDXS Stock Jump 7% Today?

The company tied up with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA using a proprietary ECO Synthesis platform.

Equity

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Codexis Inc.

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

CDXS
Codexis Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CDXS News

CDXSCodexis Inc.